Insights Into the Global Alzheimer's Disease Market, 2023-2032 – Eli Lilly's Donanemab Poised as Front-Runner for 2024 Market Debut, Set to Rival Biogen and Eisai's LEQEMBI in Emerging Therapy Arena



DUBLIN, Aug. 18, 2023 /PRNewswire/ — The “Alzheimer’s Disease – Market Insight, Epidemiology And Market Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering. This report delivers an in-depth understanding of the Alzheimer’s disease historical and forecasted…

Leave a Reply